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February 2016 Abstracts S27carcinogenesis. Using a conditional K-ras induced
lung cancer mouse model, CC-LR (CCSPCre/LSL-K-
rasG12D), we previously showed that K-ras mutant
lung tumors have intrinsic inﬂammatory characteris-
tics. This was associated with activation of NF-kB
pathway, release of inﬂammatory cytokines IL-6, and
IL-17A, and activation of the IL-6 responsive tran-
scription factor STAT3. We have further shown
that IL-6/STAT3 pathway, and IL-17 producing
CD4 helper T cells (Th17 cells) through their main
cytokine, IL-17A, play critical roles in promotion of
lung cancer in this model. Interleukin-22 (IL-22) is
another effecter molecule secreted by Th17 cells
which is highly expressed and produced in our K-ras
mutant mouse model. IL-22 is a unique cytokine in
the IL-10 family which seems to act exclusively on
nonhematopoietic cells, with basal IL-22R expression
in the epithelial cells and ﬁbroblast, and mostly sig-
nals through STAT3 pathway. Here we found that
genetic ablation of IL-22 in CC-LR mice (CC-LR/IL22-
KO mice) results in a signiﬁcant reduction in lung
surface tumor numbers by w54% (2.1-fold)
compared to age and sex matched control CC-LR mice.
Histopathological analysis of H&E stained lung sec-
tions also conﬁrmed reduction in number and size of
tumors and less adenomatous lesions in CC-LR/IL22-
KO mice compared to CC-LR mice. Immunohisto-
chemical staining of lung tissues with speciﬁc
markers, Ki-67, CD-31 and pSTAT3 demonstrated
signiﬁcantly lower tumor cell proliferation, angio-
genesis and STAT3 activation in CC-LR/IL22-KO mice.
IL-22 ablation also reduced the numbers of inﬂam-
matory cells in bronchoalveolar lavage ﬂuid,
decreased the expression of pro-tumor inﬂammatory
cytokines such as IL-6, IL-17 and TNFa, and increased
expression of anti-tumor inﬂammatory cytokines such
as IFNg. Recent studies have shown an association
between IL-22 and stem-cell like properties in colon
cancer. In lung cancer, populations expressing
NANOG, SOX2, Oct4 and/or aldehyde dehydrogenase
activity are enriched with stemness properties.
Interestingly, in CC-LR/IL22-KO mice we found sig-
niﬁcant reduction in expression of NANOG, SOX2 and
Oct4. Thus, we conclude that IL-22 promotes K-ras
mutant lung tumorigenesis by inducing a pro-tumor
inﬂammatory microenvironment with proliferative
and angiogenic properties as well as protecting
stemness characteristic in epithelial/tumor cells.
Therefore, we propose pharmacological targeting
of IL-22 as a potential therapeutic strategy in com-
bination with conventional cytotoxic therapy, immune
check point blockade, or other targeted therapies
(e.g. MEK inhibition) for lung cancer patients with
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Purpose: To investigate serial changes of tumor hypoxia
in response to ablative radiation treatment by using
various clinical and pre-clinical methods in order to
propose an optimal fractionation schedule for stereo-
tactic ablative radiotherapy (SABR).
Methods and Materials: Syngeneic Lewis lung carci-
nomas were grown either orthotopically or subcuta-
neously in C57BL/6 mice and were irradiated with a
single dose of 15 Gy to mimic SABR used in the clinic.
Serial [18F]-misonidazole (F-MISO) positron emission
tomography (PET) imaging, pimonidazole FACS ana-
lyses, hypoxia-responsive element (HRE)-driven
bioluminescence, and Hoechst 33342 perfusion were
performed before irradiation (d-1), at 6 hours (d0),
2 (d2), and 6 days (d6) after irradiation for both
subcutaneous and orthotopic lung tumors. For F-MISO,
the tumor-to-background activity ratio (TBR) was
calculated.
Results: We observed that hypoxic signals were too
low to quantitate for orthotopic tumors by F-MISO
PET and HRE-driven bioluminescence imaging. In
subcutaneous tumors we observed that TBR values
were 2.87 ± 0.483 at d-1, 1.67 ± 0.116 at d0, 2.92 ±
0.334 at d2, and 2.13 ± 0.385 at d6, indicating that
tumor hypoxia decreased after irradiation and
returned to the pretreatment levels and then slightly
decreased by 2 and 6 days post-radiation, respectively.
Pimonidazole analysis also revealed similar patterns.
By using Hoechst 33342 vascular perfusion dye and
CD31 co-immunostaining, we found that there was a
rapid and transient vascular collapse, which may have
resulted in poor intratumoral perfusion of F-MISO PET
tracer and pimonidazole at d0 hence leading to the
decreased hypoxic signals.
Conclusions: We found tumor hypoxia levels to be
returned to the pretreatment levels by 2 days after
irradiation, hence supporting the use of current frac-
tionation intervals of SABR being given at least 2 days.
Our results also indicate that SABR may produce a rapid
and transient vascular collapse in tumors.
